DIN 02467542 — VOSEVI 100 MG; 400 MG; 100 MG
VOSEVI is a tablet of Sofosbuvir / Velpatasvir / Voxilaprevir marketed by GILEAD SCIENCES CANADA INC. The full Sofosbuvir / Velpatasvir / Voxilaprevir monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02467542
- Brand name
- VOSEVI
- Active ingredient
- Sofosbuvir / Velpatasvir / Voxilaprevir
- Strength
- 100 MG; 400 MG; 100 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- GILEAD SCIENCES CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Pangenotypic direct-acting antiviral combination (NS5B polymerase inhibitor / NS5A inhibitor / NS3-4A protease inhibitor)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.